Patent US5608156A successfully refreshed from Google Patents.
Patent US4684269A successfully refreshed from Google Patents.
Patent US4309415A successfully refreshed from Google Patents.
US4309415A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and composition for treating inflammatory disorders
Assignee: Verronmay Ltd
•
Filing: 1979-04-11
•
Granted: 1982-01-05
•
Expires: 1999-04-11
Abstract
Abstract Compositions and use of gamma -linolenic acid and related materials with (i) zinc, beta -lactam antibiotics or other materials enhancing physiological 1-series PG synthesis and/or (ii) colchicine, Vinca alkaloids or other materials enhancing physiological synthesis of thromboxane A2, for treatment of inflammatory disorders.
Inventors
- 👤 David F. Horrobin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 18:44
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K31/00; A61K31/185; A61K31/19; A61K31/20; A61K31/21; A61K31/215; A61K31/22; A61K31/23; A61K31/33; A61K31/335; A61K31/34; A61K31/395; A61K31/40; A61K31/41; A61K31/425; A61K31/429; A61K31/43; A61K31/435; A61K31/47; A61K31/475; A61K31/557; A61K33/00; A61K33/24; A61K33/30; A61K45/00; A61K45/06; A61P; A61P13/00; A61P13/02; A61P15/00; A61P29/00; A61P35/00; A61P37/00; A61P43/00
Claims Analysis
Total Claims: 45
Claim 1
Independent Claim
55 words
A pharmaceutical composition useful for the treatment of inflammatory disorders comprising: (a) an effective amount of γ-linolenic acid or physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or physiologically functional derivative thereof, and (b) an effective, conjoint amount of another material enhancing the synthesis or action of thromoboxane A2, alone or in an acceptable pharmaceutical vehicle.
Claim 2
Dependent Claim
55 words
A pharmaceutical composition useful for the treatment of inflammatory disorders comprising: (a) an effective amount of γ-linolenic acid or physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or physiologically functional derivative thereof, and (b) an effective, conjoint amount of another material enhancing the synthesis or action of thromoboxane A2, alone or in an acceptable pharmaceutical vehicle.
Claim 3
Dependent Claim
61 words
A pharmaceutical composition useful for the treatment of inflammatory disorders comprising: (a) an effective amount of γ-linolenic acid or physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or physiologically functional derivative thereof, and (b) an effective, conjoint amount of a material selected from colchicine, vinblastine, vincristine, and other Vinca alkaloids, griseofulvin, amantadine, melatonin, and interferon, alone or in an acceptable pharmaceutical vehicle.
Claim 4
Dependent Claim
61 words
A pharmaceutical composition useful for the treatment of inflammatory disorders comprising: (a) an effective amount of γ-linolenic acid or physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or physiologically functional derivative thereof, and (b) an effective, conjoint amount of a material selected from colchicine, vinblastine, vincristine, and other Vinca alkaloids, griseofulvin, amantadine, melatonin, and interferon, alone or in an acceptable pharmaceutical vehicle.
Claim 5
Dependent Claim
34 words
The composition of claim 1 or 2, presented for administration in doses comprising 0.05 to 10 g of (a) calculated as γ-linolenic acid, or one half one third or one quarter of said amount.
Claim 6
Dependent Claim
34 words
The composition of claim 1 or 2, presented for administration in doses comprising 0.1 to 1 g of (a) calculated as γ-linolenic acid or one half one third or one quarter of said amount.
Claim 7
Dependent Claim
75 words
The composition of claim 2, presented in daily or where specified weekly doses for administration in doses comprising: 0.3 to 15 mg colchicine or 100 to 1000 mg amantidine or 0.5 to 5 g griseofulvin or 35 to 350 mg vinblastine (weekly) or 7 to 70 mg vincristine (weekly) or 1×10 5 to 1×10 8 units interferon or 10 mg to 5 g melatonin or one half one third or one quarter of said amount.
Claim 8
Dependent Claim
53 words
A pharmaceutical composition useful for the treatment of inflammatory disorders comprising (a) an effective amount of γ-linolenic acid or physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or physiologically functional derivative thereof, and (b) an effective, conjoint amount of a material selected from penicillamine, phenformin and levamisole, alone or in an acceptable pharmaceutical vehicle.
Claim 9
Dependent Claim
53 words
A pharmaceutical composition useful for the treatment of inflammatory disorders comprising (a) an effective amount of γ-linolenic acid or physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or physiologically functional derivative thereof, and (b) an effective, conjoint amount of a material selected from penicillamine, phenformin and levamisole, alone or in an acceptable pharmaceutical vehicle.
Claim 10
Dependent Claim
32 words
The composition of claim 6, presented for administration in doses comprising 0.05 to 10 g of (a) calculated as γ-linolenic acid, or one half one third or one quarter of said amounts.
Claim 11
Dependent Claim
32 words
The composition of claim 6, presented for administration in doses comprising 0.1 to 1 g of (a) calculated as γ-linolenic acid, or one half one third or one quarter of said amounts.
Claim 12
Dependent Claim
42 words
The composition of claim 6, presented for administration in doses comprising: 50 mg to 10 g: penicillamine or 10 mg to 5 g: phenformin or 10 mg to 2 g: levamisole or one half one third or one quarter of said amount.
Claim 13
Dependent Claim
28 words
The composition of claim 1, comprising further (c) a conjoint amount of a material influencing the 1-series/2-series PG balance in the body in favor of the 1-series PG's.
Claim 14
Dependent Claim
22 words
The composition of claim 2, comprising further (c) a conjoint amount of physiologically assimilable zinc, penicillamine, phenformin, levamisole or a β-lactam antibiotic.
Claim 15
Dependent Claim
17 words
The composition of claim 11, wherein the antibiotic is a natural or semi-synthetic penicillin or cephalosporin antibiotic.
Claim 16
Dependent Claim
24 words
The composition of claim 11, wherein the antibiotic is selected from penicillin G, penicillin N, penicillin V, cephalothin, ampicillin, amoxycillin, cloxacillin, cephalexin and cephaloglycin.
Claim 17
Dependent Claim
32 words
The composition of claim 11, 12 or 13 presented for administration in doses comprising 0.5 to 3 g of the antibiotic or one half one third or one quarter of said amount.
Claim 18
Dependent Claim
42 words
The composition of claim 11, presented for administration in doses comprising: 50 mg to 10 g: penicillamine or 10 mg to 5 g: phenformin or 10 mg to 2 g: levamisole or one half one third or one quarter of said amount.
Claim 19
Dependent Claim
30 words
The composition of claim 11, presented for administration in doses comprising 2.5 to 800 mg assimilable zinc calculated as the metal, or one half one third or one quarter thereof.
Claim 20
Dependent Claim
30 words
The composition of claim 11, presented for administration in doses comprising 10 to 200 mg assimilable zinc calculated as the metal, or one half one third or one quarter thereof.
Claim 21
Dependent Claim
30 words
The composition of claim 11, presented for administration in doses comprising 10 to 80 mg assimilable zinc calculated as the metal, or one half one third or one quarter thereof.
Claim 22
Dependent Claim
18 words
A composition according to claim 11 wherein the zinc is present as a zinc oleate, γ-linolenate or dihomo-γ-linolenate.
Claim 23
Independent Claim
55 words
A method of treating inflammation, comprising administering to a person suffering therefrom an effective amount of γ-linolenic acid or a physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or a physiologically functional derivative thereof, and an effective conjoint amount of a material influencing the 1-series/2-series PG balance in the body in factor of the 1-series PG's.
Claim 24
Independent Claim
55 words
A method of treating inflammation, comprising administering to a person suffering therefrom an effective amount of γ-linolenic acid or a physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or a physiologically functional derivative thereof, and an effective conjoint amount of a material influencing the 1-series/2-series PG balance in the body in factor of the 1-series PG's.
Claim 25
Independent Claim
53 words
A method of treating inflammation, comprising administering to a person suffering therefrom an effective amount of γ-linolenic acid or a physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or a physiologically functional derivative thereof, and an effective conjoint amount of a material selected from physiologically assimilible zinc, penicillamine, phenformin, levamisole, or a βγ-lactam antibiotic.
Claim 26
Independent Claim
53 words
A method of treating inflammation, comprising administering to a person suffering therefrom an effective amount of γ-linolenic acid or a physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or a physiologically functional derivative thereof, and an effective conjoint amount of a material selected from physiologically assimilible zinc, penicillamine, phenformin, levamisole, or a βγ-lactam antibiotic.
Claim 27
Independent Claim
48 words
A method of treating inflammation, comprising administering to a person suffering therefrom an effective amount of γ-linolenic acid or a physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or a physiologically functional derivative thereof and an effective conjoint amount of a material enhancing synthesis or action of thromboxane A2.
Claim 28
Independent Claim
48 words
A method of treating inflammation, comprising administering to a person suffering therefrom an effective amount of γ-linolenic acid or a physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or a physiologically functional derivative thereof and an effective conjoint amount of a material enhancing synthesis or action of thromboxane A2.
Claim 29
Independent Claim
63 words
A method of treating inflammation, comprising administering to a person suffering therefrom an effective amount of γ-linolenic acid or a physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or a physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or a physiologically functional derivative thereof and an effective conjoint amount a material selected from colchicine, vinblastine, vincristine and other Vinca alkalodis, griseofulvin, amantadine, melatonin, and interferon.
Claim 30
Independent Claim
63 words
A method of treating inflammation, comprising administering to a person suffering therefrom an effective amount of γ-linolenic acid or a physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or a physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or a physiologically functional derivative thereof and an effective conjoint amount a material selected from colchicine, vinblastine, vincristine and other Vinca alkalodis, griseofulvin, amantadine, melatonin, and interferon.
Claim 31
Independent Claim
72 words
A method of treating inflammation, comprising administering to a person suffering therefrom (1) an effective amount of γ-linolenic acid or a physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or physiologically functional derivative thereof, (2) an effective conjoint amount of physiologically assimilable zinc, penicillamine, phenformin, levamisole, or a β-lactam antibiotic, and (3) an effective conjoint amount of a material selected from colchicine, vinblastine, vincristine and other Vinca alkaloids, griseofulvin, amantadine, melatonin, and interferon.
Claim 32
Independent Claim
72 words
A method of treating inflammation, comprising administering to a person suffering therefrom (1) an effective amount of γ-linolenic acid or a physiologically functional derivative thereof and/or dihomo-γ-linolenic acid or physiologically functional derivative thereof, (2) an effective conjoint amount of physiologically assimilable zinc, penicillamine, phenformin, levamisole, or a β-lactam antibiotic, and (3) an effective conjoint amount of a material selected from colchicine, vinblastine, vincristine and other Vinca alkaloids, griseofulvin, amantadine, melatonin, and interferon.
Claim 33
Dependent Claim
18 words
A method according to claim 21, wherein said antibiotic is a natural or semi-synthetic penicillin or cephalosporin antibiotic.
Claim 34
Dependent Claim
25 words
A method according to claim 25, wherein said antibiotic is selected from penicillin G, penicillin N, penicillin V, cephalothin, ampicillin, amoxycillin, cloxacillin, cephalexin and cephaloglycin.
Claim 35
Dependent Claim
24 words
A method according to claim 20, wherein the daily amount of said acid or derivative is 0.05 to 10 g calculated as γ-linolenic acid.
Claim 36
Dependent Claim
20 words
A method according to claim 27, wherein the daily amount of said acid or derivative is 0.1 to 5 g.
Claim 37
Dependent Claim
22 words
A method according to claim 21, wherein the daily amount of said zinc is 2.5 to 800 mg calculated as the metal.
Claim 38
Dependent Claim
16 words
A method according to claim 29, wherein the amount of zinc is 10 to 200 mg.
Claim 39
Dependent Claim
16 words
A method according to claim 29, wherein the amount of zinc is 10 to 80 mg.
Claim 40
Dependent Claim
37 words
A method according to claim 21, wherein the daily amount of said penicillamine, phenformin or levamisole is 50 mg to 10 g pencillamine or 10 mg to 5 g phenformin or 10 mg to 2 g levamisole.
Claim 41
Dependent Claim
21 words
A method according to claim 21, 25, or 26, wherein the daily amount of said antibiotic is 0.3 to 5 g.
Claim 42
Dependent Claim
29 words
A method according to claim 22, further comprising administering an effective, conjoint amount of a material influencing the 1-series/2-series PG balance in the body in favor of 1-series PG's.
Claim 43
Dependent Claim
29 words
A method according to claim 23, further comprising administering an effective, conjoint amount of a material influencing the 1-series/2-series PG balance in the body in favor of 1-series PG's.
Claim 44
Dependent Claim
69 words
A method according to claim 23 or 35 when said selected material is administered in a daily or where specified weekly amount of: 0.3 to 15 mg colchicine or 100 to 1000 mg amantadine or 0.5 to 5 g griseofulvin or 35 to 350 mg vinblastine (weekly) or 7 to 70 mg vincristine (weekly) or 1×10 5 to 1×10 8 units interferon or 10 mg to 5 g melatonin
Claim 45
Dependent Claim
20 words
A method according to claim 21 in which said zinc is in the form of zinc oleate, γ-linolenate or dihomo-γ-linolenate.
References Cited (Backward Citations)
US3949072A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-01-04 | 1985-07-06 | 1986-01-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-01-04 | 1989-07-06 | 1990-01-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-01-04 | 1993-07-06 | 1994-01-05 | $7700.00 | Window Closed / Lapsed |